Research Article| Volume 36, ISSUE 11, P1665-1674, November 01, 2014

Hemoglobin Stability and Patient Compliance With Darbepoetin Alfa in Peritoneal Dialysis Patients After the Implementation of the Prospective Payment System

Published:September 23, 2014DOI:



      Since the Centers for Medicare & Medicaid Services implemented the End-Stage Renal Disease Prospective Payment System, dialysis providers have increasingly focused on balancing resource utilization and quality outcomes for the treatment of anemia in patients undergoing peritoneal dialysis. Limited data exist regarding anemia management outcomes for these patients in US-based dialysis centers after the implementation of the new payment system.


      This was a retrospective, observational, cohort study of stable PD patients with end-stage renal disease who received darbepoetin alfa for anemia management over a 15-month period (April 1, 2011–June 29, 2012). The medication was administered by staff in the home-training unit instead of being self-administered at home. The primary end point was mean quarterly hemoglobin (Hb) levels. Variability in Hb levels was assessed over the 5 quarters by using repeated measures ANOVA to test for differences in the observed mean SDs.


      In the 139 adult patients on stable peritoneal dialysis and meeting the eligibility criteria, mean (SD) Hb level by quarter was 10.8 (1.2) g/dL in quarters 2 and 3 of 2011, 10.5 (1.1) g/dL in quarter 4 of 2011, and 10.4 (1.1) g/dL in quarters 1 and 2 of 2012. Hb levels were stable (mean SDs, 0.58–0.72) over the 5 quarters of the study. Patient compliance with attendance for all scheduled home training unit visits was 84%.


      PD patients who underwent darbepoetin alfa administration and twice-monthly laboratory testing in the home-training unit had stable Hb levels. Despite more frequent center visits compared with a home-administered approach, patient compliance was high.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Therapeutics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Centers for Medicare & Medicaid Services
        Medicare Program; end stage renal disease prospective payment system: final rule.
        Fed Regist. 2010; 75: 49029-49214
        • Hornberger J.
        • Hirth R.A.
        Financial implications of choice of dialysis type of the revised Medicare payment system: an economic analysis.
        Am J Kidney Dis. 2012; 60: 280-287
        • Solid C.A.
        • Collins A.J.
        Changes and alternatives for dialysis facilities under the bundled payment plan.
        Nephrol News Issues. 2013; 27: 30-32
      1. Arbor Research Collaborative for Health/University of Michigan Kidney Epidemiology and Cost Center. End-stage Renal Disease (ESRD) Quality Measure Development and Maintenance. Clinical Technical Expert Panel Meeting Draft Summary Report 2012.

        • Centers for Medicare, Medicaid Services HHS
        Medicare program; end-stage renal disease prospective payment system, quality incentive program, and durable medical equipment, prosthetics, orthotics, and supplies.
        Fed Regist. 2013; 78: 72155-72253
        • Nicoletta P.
        • Bernardini J.
        • Dacko C.
        • et al.
        Compliance with subcutaneous erythropoietin in peritoneal dialysis patients.
        Adv Perit Dial. 2000; 16: 90-92
        • Wazny L.D.
        • Stojimirovic B.B.
        • Heidenheim P.
        • Blake P.G.
        Factors influencing erythropoietin compliance in peritoneal dialysis patients.
        Am J Kidney Dis. 2002; 40: 623-628
      2. University of Michigan Kidney Epidemiology and Cost Center. 2013 Dialysis Facility Report, August 2013. Accessed November 4, 2014.

        • Aranesp® (darbepoetin alfa) prescribing information
        Amgen Inc, Thousand Oaks, CAMay 2012
      3. (Epogen® (Epoetin alfa) prescribing information) Amgen Inc, Thousand Oaks, CAMay 2012
        • Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group
        KDIGO clinical practice guideline for anemia in chronic kidney disease.
        Kidney Int. 2012; 2: 279-335
        • Brunelli S.M.
        • Monda K.L.
        • Burkart J.M.
        • et al.
        Early Trends from the Study to Evaluate the Prospective Payment System Impact on Small Dialysis Organizations (STEPPS).
        AJKD. 2013; 61: 947-956
        • Gilg J.
        • Webb L.
        • Feest T.
        • Fogarty D.
        UK Renal Registry 13th Annual Report (December 2010): Chapter 9: haemoglobin, ferritin and erythropoietin amongst UK adult dialysis patients in 2009: national and centre-specific analyses.
        Nephron Clin Pract. 2011; 119: c149-c177
      4. Pen Y, Kats A, Gilbertson D, et al. Patterns of anemia management in patients receiving peritoneal dialysis. Abstract and poster presented at: National Kidney Foundation, Spring Clinical Meetings; April 22-26, 2014; Las Vegas, NV.

      5. U.S. Renal Data System, USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2010.

        • Pfeffer M.A.
        • Burdmann E.A.
        • Chen C.Y.
        • et al.
        A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease.
        N Engl J Med. 2009; 361: 2019-2032
        • Swedberg K.
        • Young J.B.
        • Anand I.S.
        Treatment of anemia with darbepoetin alfa in systolic heart failure.
        N Engl J Med. 2013; 368: 1210-1219
        • Fang Y.W.
        • Chang C.H.
        Subcutaneous administration of darbepoetin alfa effectively maintains hemoglobin concentrations at extended dose intervals in peritoneal dialysis patients.
        Perit Dial Int. 2009; 29: 199-203
        • Feriani M.
        • De Meester J.M.
        • McMahon L.P.
        • et al.
        Extended dosing of darbepoetin alfa in peritoneal dialysis patients.
        BMC Nephrol. 2011; 12: 13
        • Vanrenterghem Y.
        • Barany P.
        • Mann J.F.
        • et al.
        Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients.
        Kidney Int. 2002; 62: 2167-2175
        • Besarab A.
        • Salifu M.O.
        • Lunde N.M.
        • et al.
        Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease.
        Clin Ther. 2007; 29: 626-639
        • Walker R.
        • Pussell B.A.
        • Group A.R.A.
        Fluctuations in haemoglobin levels in haemodialysis, pre-dialysis and peritoneal dialysis patients receiving epoetin alpha or darbepoetin alpha.
        Nephrology (Carlton). 2009; 14: 689-695
        • Selby N.M.
        • Fonseca S.A.
        • Fluck R.J.
        • Taal M.W.
        Hemoglobin variability with epoetin beta and continuous erythropoietin receptor activator in patients on peritoneal dialysis.
        Perit Dial Int. 2012; 32: 177-182
        • Neumann M.E.
        Moderate growth for dialysis providers, but rebasing, ACO participation will impact long-term picture.
        Nephrol News Issues. 2013; 27: 18
      6. U.S. Renal Data System, USRDS 2012 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2012.

        • Jaar B.G.
        • Plantinga L.C.
        • Crews D.C.
        • et al.
        Timing, causes, predictors and prognosis of switching from peritoneal dialysis to hemodialysis: a prospective study.
        BMC Nephrol. 2009; 10: 3
        • Foley R.N.
        • Solid C.A.
        • Lamb K.
        Perihospitalization patterns of hemoglobin levels and erythropoiesis-stimulating agent doses in US hemodialysis patients, 1998–2009.
        Hemodialysis Int. 2014; 18: 24-31